HDAC9 and acute myeloid leukemia: A multicenter randomized phase II trial by the German AML study group (AMLSG) is already underway to test the benefit of decitabine, in combination with the HDAC inhibitor valproic acid and/or ATRA in patients not eligible for induction chemotherapy (DECIDER Study, AMLSG 14-09, NCT00867672).